LEXICON GENETICS INC jetzt einsammeln!!!!! - 500 Beiträge pro Seite
eröffnet am 11.12.06 19:08:01 von
neuester Beitrag 14.06.07 18:24:43 von
neuester Beitrag 14.06.07 18:24:43 von
Beiträge: 8
ID: 1.099.613
ID: 1.099.613
Aufrufe heute: 0
Gesamt: 1.486
Gesamt: 1.486
Aktive User: 0
ISIN: US5288723027 · WKN: A14SSK · Symbol: LXRX
1,6700
USD
-5,65 %
-0,1000 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
14.05.24 · globenewswire  |
09.05.24 · globenewswire |
02.05.24 · globenewswire |
29.04.24 · globenewswire |
29.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,1800 | +28,02 | |
| 1,9900 | +27,56 | |
| 1,2900 | +24,04 | |
| 2,7200 | +21,97 | |
| 1,0200 | +20,60 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,0600 | -14,88 | |
| 2,9000 | -16,91 | |
| 2,2001 | -20,57 | |
| 0,8401 | -23,63 | |
| 0,7601 | -23,98 |
Feedback
kaufen!
Begründung??????????
morgen gibts eine Conference
Lexicon Genetics to Present at RBC Capital Markets Healthcare Conference
Thursday December 7, 5:00 pm ET
THE WOODLANDS, Texas, Dec. 7 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, will participate in two panels at the RBC Capital Markets Healthcare Conference at The Westin, New York City on Thursday, December 14, 2006. The panels are:
- Pipelines & Partners: Building Through Acquisition & Licensing at
8:00 a.m. EST
- Better Chemistry = Better Drugs at 9:00 a.m. EST
The live audio webcast of Lexicon's panel discussions may be accessed on its corporate website at http://www.lexicon-genetics.com . Archived versions of the webcasts will be available on the website through December 22, 2006.
About Lexicon Genetics
Lexicon Genetics is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs addressing these targets. For targets that the company believes have high pharmaceutical value, it engages in programs for the discovery and development of small molecule, antibody and protein drugs. Lexicon has advanced knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon is working both independently and through collaborations and strategic alliances to accelerate the development and commercialization of its discoveries. Additional information about Lexicon is available through its corporate website, http://www.lexicon-genetics.com .
Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2005, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
--------------------------------------------------------------------------------
Source: Lexicon Genetics Incorporated
Lexicon Genetics to Present at RBC Capital Markets Healthcare Conference
Thursday December 7, 5:00 pm ET
THE WOODLANDS, Texas, Dec. 7 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, will participate in two panels at the RBC Capital Markets Healthcare Conference at The Westin, New York City on Thursday, December 14, 2006. The panels are:
- Pipelines & Partners: Building Through Acquisition & Licensing at
8:00 a.m. EST
- Better Chemistry = Better Drugs at 9:00 a.m. EST
The live audio webcast of Lexicon's panel discussions may be accessed on its corporate website at http://www.lexicon-genetics.com . Archived versions of the webcasts will be available on the website through December 22, 2006.
About Lexicon Genetics
Lexicon Genetics is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs addressing these targets. For targets that the company believes have high pharmaceutical value, it engages in programs for the discovery and development of small molecule, antibody and protein drugs. Lexicon has advanced knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon is working both independently and through collaborations and strategic alliances to accelerate the development and commercialization of its discoveries. Additional information about Lexicon is available through its corporate website, http://www.lexicon-genetics.com .
Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2005, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
--------------------------------------------------------------------------------
Source: Lexicon Genetics Incorporated
einsammeln
Trading Spotlight
Allzeittief
die kennt auch nur noch eine Richtung
sind die Shorts Schuld?
Settlement Date .... Short Interest Avg... Daily Share Volume ..... Days to Cover
May 15, 2007 .........5,374,311 ..............280,552 ........19.16
oder taugt der Laden einfach nichts?
2 Produkte in Phase 1 und der Rest noch weiter hinten. Die nächsten 5 JAhre wird da wohl nichts gehen.
sind die Shorts Schuld?
Settlement Date .... Short Interest Avg... Daily Share Volume ..... Days to Cover
May 15, 2007 .........5,374,311 ..............280,552 ........19.16
oder taugt der Laden einfach nichts?
2 Produkte in Phase 1 und der Rest noch weiter hinten. Die nächsten 5 JAhre wird da wohl nichts gehen.
Antwort auf Beitrag Nr.: 29.896.069 von wohinistmeinGeld am 14.06.07 18:15:36hät ich bloß die Klappe gehalten, kaum geschrieben schon ein neues Allzeittief.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,19 | |
| +2,15 | |
| -0,90 | |
| -0,80 | |
| -0,85 | |
| 0,00 | |
| -2,52 | |
| -0,87 | |
| +0,81 | |
| -0,93 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 83 | ||
| 71 | ||
| 51 | ||
| 45 | ||
| 31 | ||
| 30 | ||
| 30 | ||
| 28 | ||
| 25 | ||
| 22 |
